Jameel M Inal

List of Publications by Year
in descending order

65 papers	11,037 citations	126907 33 h-index	118850 62 g-index
67 all docs	67 docs citations	67 times ranked	16353 citing authors

#	Article	IF	Citations
1	Communication is key: extracellular vesicles as mediators of infection and defence during hostâ€“microbe interactions in animals and plants. FEMS Microbiology Reviews, 2022, 46, .	8.6	33
2	Prostate cancer and microfluids. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 455-470.	1.6	6
3	Biological Factors Linking ApoE Îµ4 Variant and Severe COVID-19. Current Atherosclerosis Reports, 2020, 22, 70.	4.8	8
4	Complement-mediated Extracellular Vesicle release as a measure of endothelial dysfunction and prognostic marker for COVID-19 in peripheral blood - Letter to the Editor. Clinical Hemorheology and Microcirculation, 2020, 75, 383-386.	1.7	9
5	COVIDâ€19 comorbidities, associated procoagulant extracellular vesicles and venous thromboembolisms: a possible link with ethnicity?. British Journal of Haematology, 2020, 190, e218-e220.	2.5	14
6	Peptidylarginine Deiminase Isozyme-Specific PAD2, PAD3 and PAD4 Inhibitors Differentially Modulate Extracellular Vesicle Signatures and Cell Invasion in Two Glioblastoma Multiforme Cell Lines. International Journal of Molecular Sciences, 2020, 21, 1495.	4.1	43
7	Plasma mEV levels in Ghanain malaria patients with low parasitaemia are higher than those of healthy controls, raising the potential for parasite markers in mEVs as diagnostic targets. Journal of Extracellular Vesicles, 2020, 9, 1697124.	12.2	24
8	Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy. Clinical Science, 2020, 134, 1301-1304.	4.3	75
9	Peptidylarginine Deiminase Inhibitors Reduce Bacterial Membrane Vesicle Release and Sensitize Bacteria to Antibiotic Treatment. Frontiers in Cellular and Infection Microbiology, 2019, 9, 227.	3.9	61
10	Cannabidiol Is a Novel Modulator of Bacterial Membrane Vesicles. Frontiers in Cellular and Infection Microbiology, 2019, 9, 324.	3.9	63
11	Mesenchymal Stromal Cell Derived Extracellular Vesicles Reduce Hypoxia-Ischaemia Induced Perinatal Brain Injury. Frontiers in Physiology, 2019, 10, 282.	2.8	57
12	Cannabidiol Affects Extracellular Vesicle Release, miR21 and miR126, and Reduces Prohibitin Protein in Glioblastoma Multiforme Cells. Translational Oncology, 2019, 12, 513-522.	3.7	55
13	Peptidylarginine Deiminases Post-Translationally Deiminate Prohibitin and Modulate Extracellular Vesicle Release and MicroRNAs in Glioblastoma Multiforme. International Journal of Molecular Sciences, 2019, 20, 103.	4.1	63
14	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018, 7, 1535750.	12.2	6,961
15	Cannabidiol (CBD) Is a Novel Inhibitor for Exosome and Microvesicle (EMV) Release in Cancer. Frontiers in Pharmacology, 2018, 9, 889.	3.5	115
16	A new landscape of hostâ€“protozoa interactions involving the extracellular vesicles world. Parasitology, 2018, 145, 1521-1530.	1.5	18
17	Microvesicles released from Giardia intestinalis disturb host-pathogen response in vitro. European Journal of Cell Biology, 2017, 96, 131-142.	3.6	72
18	The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy. International Journal of Cancer, 2017, 141, 428-436.	5.1	67

#	Article	IF	Citations
19	Chloramidine/Bisindolylmaleimide-I-Mediated Inhibition of Exosome and Microvesicle Release and Enhanced Efficacy of Cancer Chemotherapy. International Journal of Molecular Sciences, 2017, 18, 1007.	4.1	132
20	Peptidylarginine Deiminasesâ€"Roles in Cancer and Neurodegeneration and Possible Avenues for Therapeutic Intervention via Modulation of Exosome and Microvesicle (EMV) Release?. International Journal of Molecular Sciences, 2017, 18, 1196.	4.1	70
21	Treatment of Prostate Cancer Using Deimination Antagonists and Microvesicle Technology. , 2017, , 413-425.		0
22	Exosomes serve as tumour markers for personalized diagnostics owing to their important role in cancer metastasis. Journal of Extracellular Vesicles, 2015, 4, 27522.	12.2	228
23	A novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of PAD inhibition in sensitizing prostate cancer cells to chemotherapy. Journal of Extracellular Vesicles, 2015, 4, 26192.	12.2	126
24	Inhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces docetaxel dose required to limit tumor growth in vivo. Scientific Reports, 2015, 5, 13006.	3.3	88
25	EVpedia: a community web portal for extracellular vesicles research. Bioinformatics, 2015, 31, 933-939.	4.1	317
26	Prostate cancer cells stimulated by calcium-mediated activation ofÂprotein kinase C undergo a refractory period before re-releasing calcium-bearing microvesicles. Biochemical and Biophysical Research Communications, 2015, 460, 511-517.	2.1	15
27	Microvesicles released constitutively from prostate cancer cells differ biochemically and functionally to stimulated microvesicles released through sublytic C5b-9. Biochemical and Biophysical Research Communications, 2015, 460, 589-595.	2.1	14
28	Microfabrication of conical microfunnels for drug delivery applications. Micro and Nano Letters, 2015, 10, 355-357.	1.3	1
29	Label-free real-time acoustic sensing of microvesicle release from prostate cancer (PC3) cells using a Quartz Crystal Microbalance. Biochemical and Biophysical Research Communications, 2014, 453, 619-624.	2.1	11
30	The role of microvesicles in cancer progression and drug resistance. Biochemical Society Transactions, 2013, 41, 293-298.	3.4	36
31	Microvesiculation and Disease. Biochemical Society Transactions, 2013, 41, 237-240.	3.4	10
32	Interplay of hostâ€"pathogen microvesicles and their role in infectious disease. Biochemical Society Transactions, 2013, 41, 258-262.	3.4	36
33	Blood/plasma secretome and microvesicles. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 2317-2325.	2.3	87
34	Pulsed extremely low-frequency magnetic fields stimulate microvesicle release from human monocytic leukaemia cells. Biochemical and Biophysical Research Communications, 2013, 430, 470-475.	2.1	27
35	Coxsackievirus B transmission and possible new roles for extracellular vesicles. Biochemical Society Transactions, 2013, 41, 299-302.	3.4	35
36	Vesiclepedia: A Compendium for Extracellular Vesicles with Continuous Community Annotation. PLoS Biology, 2012, 10, e1001450.	5.6	1,064

#	Article	IF	Citations
37	<i>Trypanosoma cruzi</i> Immune Evasion Mediated by Host Cell-Derived Microvesicles. Journal of Immunology, 2012, 188, 1942-1952.	0.8	139
38	Microvesicles in Health and Disease. Archivum Immunologiae Et Therapiae Experimentalis, 2012, 60, 107-121.	2.3	59
39	A filtration-based protocol to isolate human Plasma Membrane-derived Vesicles and exosomes from blood plasma. Journal of Immunological Methods, 2011, 371, 143-151.	1.4	115
40	Human Plasma Membrane-Derived Vesicles Halt Proliferation and Induce Differentiation of THP-1 Acute Monocytic Leukemia Cells. Journal of Immunology, 2010, 185, 5236-5246.	0.8	54
41	Involvement of lectin pathway activation in the complement killing of Giardia intestinalis. Biochemical and Biophysical Research Communications, 2010, 395, 382-386.	2.1	34
42	Human plasma membrane-derived vesicles inhibit the phagocytosis of apoptotic cells â€“ Possible role in SLE. Biochemical and Biophysical Research Communications, 2010, 398, 278-283.	2.1	51
43	Red cell PMVs, plasma membrane-derived vesicles calling out for standards. Biochemical and Biophysical Research Communications, 2010, 399, 465-469.	2.1	29
44	Role of early lectin pathway activation in the complement-mediated killing of Trypanosoma cruzi. Molecular Immunology, 2009, 47, 426-437.	2.2	82
45	The intracellular Trypanosoma cruzi induces the release from monocytes of plasma membrane-derived microvesicles which protect the parasite from host complement. Molecular Immunology, 2008, 45, 4173.	2.2	0
46	Complement C2 Receptor Inhibitor Trispanning Confers an Increased Ability to Resist Complementâ€Mediated Lysis in<i>Trypanosoma cruzi</i>. Journal of Infectious Diseases, 2008, 198, 1276-1283.	4.0	34
47	The complement regulatory receptor CRIT is expressed in the developing kidney. Molecular Immunology, 2007, 44, 3991.	2.2	0
48	CRIT peptide interacts with factor B and interferes with alternative pathway activation. Biochemical and Biophysical Research Communications, 2006, 344, 308-314.	2.1	7
49	CRIT is expressed on podocytes in normal human kidney and upregulated in membranous nephropathy. Kidney International, 2006, 69, 1961-1968.	5.2	6
50	Expression of functional recombinant von Willebrand factor-A domain from human complement C2: a potential binding site for C4 and CRIT. Biochemical Journal, 2005, 389, 863-868.	3.7	11
51	Complement C2 receptor inhibitor trispanning: from man to schistosome. Seminars in Immunopathology, 2005, 27, 320-331.	4.0	17
52	Complement C2 Receptor Inhibitor Trispanning: A Novel Human Complement Inhibitory Receptor. Journal of Immunology, 2005, 174, 356-366.	0.8	46
53	The complement inhibitor, CRIT, undergoes clathrin-dependent endocytosis. Experimental Cell Research, 2005, 310, 54-65.	2.6	21
54	Complement Mediates the Binding of HIV to Erythrocytes. Journal of Immunology, 2004, 173, 4236-4241.	0.8	45

#	Article	IF	Citations
55	Parasite interaction with host complement: beyond attack regulation. Trends in Parasitology, 2004, 20, 407-412.	3.3	15
56	A Peptide Derived from the Parasite Receptor, Complement C2 Receptor Inhibitor Trispanning, Suppresses Immune Complex-Mediated Inflammation in Mice. Journal of Immunology, 2003, 170, 4310-4317.	0.8	17
57	Complement inhibition in renal diseases. Nephrology Dialysis Transplantation, 2003, 18, 237-240.	0.7	13
58	Phage therapy: a reappraisal of bacteriophages as antibiotics. Archivum Immunologiae Et Therapiae Experimentalis, 2003, 51, 237-44.	2.3	59
59	Complement C2 Receptor Inhibitor Trispanning and the Î²-Chain of C4 Share a Binding Site for Complement C2. Journal of Immunology, 2002, 168, 5213-5221.	0.8	42
60	ASchistosomaprotein, Sh-TOR, is a novel inhibitor of complement which binds human C2. FEBS Letters, 2000, 470, 131-134.	2.8	34
61	Schistosoma TOR (trispanning orphan receptor), a novel, antigenic surface receptor of the blood-dwelling, Schistosoma parasite. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1999, 1445, 283-298.	2.4	22
62	Ï†20, A Temperate Bacteriophage Isolated from Bacillus anthracis Exists as a Plasmidial Prophage. Current Microbiology, 1996, 32, 171-175.	2.2	23
63	Bacillus thuringiensis subsp. aizawai generalized transducing phage 4HD248 : restriction site map and potential for fine-structure chromosomal mapping. Microbiology (United Kingdom), 1996, 142, 1409-1416.	1.8	3
64	Sequence and immunogenicity of the 23-kDa transmembrane antigen of Schistosoma haematobium. Molecular and Biochemical Parasitology, 1995, 74, 217-221.	1.1	12
65	Generalized transduction inBacillus thuringiensisvar.aizawai. Journal of Applied Bacteriology, 1992, 72, 87-90.	1.1	3